Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

Susan Halabi(Duke University), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Philip W. Kantoff(Dana-Farber Brigham Cancer Center), Brent A. Blumenstein(Dana-Farber Cancer Institute), Ellis Levine(University of Maryland, Baltimore), Ellen B. Kaplan(University of Maryland, Baltimore), Eric J. Small(CancerCare Manitoba), Nancy A. Dawson(University of Maryland, Baltimore), Michael W. Kattan(Memorial Sloan Kettering Cancer Center)
Journal of Clinical Oncology
March 27, 2003
10.1200/jco.2003.06.100
Cited by 678

Related Papers

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k